**Summary of RUA Life Sciences PLC Final Results for the Period Ended 30 September 2025**
RUA Life Sciences PLC, a medical device-focused CDMO specializing in implantable textile components and devices, announced its audited final results for the 18-month period ended 30 September 2025. The company achieved significant milestones, including
1. **Revenue Growth**
Revenue doubled to £6.7 million (from £2.2 million in the 12 months to March 2024), with a 104% like-for-like growth.
CDMO revenues increased to £5.8 million (from £1.7 million in FY24).
Biomaterials revenues grew to £914000 (from £496000 in FY24)despite currency headwinds.
2. **Profitability Improvement**
EBITDA improved by £2.0 million to £0.4 million (from a £1.6 million loss in FY24).
Loss before tax reduced by 85% to £0.2 million (from £2.0 million in FY24).
3. **Strategic Acquisitions**
Acquired ABISS for £68k, generating a £0.9 million bargain purchase gain and strengthening the CDMO business.
4. **Cost Management**
Reduced R&D spend to £438,000 (from £873,000 in FY24) while focusing on commercial activities.
5. **Cash Position**
Year-end cash stood at £3.25 million (down from £3.93 million in FY24), after repaying a £0.11 million mortgage.
6. **Strategic Focus**
Pursuing commercialization of IP in RUA Vascular and RUA Structural Heart.
Expanding services and customer base to drive future growth.
**Outlook**
The company expects continued growth in Biomaterials and Contract Manufacturing, with a focus on exploiting its IP portfolio. Management remains confident in achieving profitability and expanding its market presence.
**Chairman’s Statement**
Geoff Berg highlighted the achievement of two-year objectives, including doubling revenues and reducing cash burn, ahead of schedule. The acquisition of ABISS and strong trading performance were key drivers. The company aims to build on this success by broadening services and expanding its customer base.
**Financial Highlights**
Revenue£6.7 million (18 months) vs £2.2 million (12 months in FY24).
Loss before tax£0.2 million vs £2.0 million in FY24.
EBITDA£0.4 million vs £1.6 million loss in FY24.
Cash£3.25 million at period end.
**Strategic Initiatives**
Focus on international growth through licensing and medical device manufacturing.
Leveraging IP to develop new product ranges and partnerships.
**Conclusion**
RUA Life Sciences demonstrated strong financial and operational progress, positioning itself for sustainable growth and profitability in the medical device industry.